The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation

British Journal of Pharmacology

Volumn 171, Issue 9, 2014, Pages 2308-2320

  Skinner, M ^a   Philp, K ^a   Lengel, D ^a   Coverley, L ^a   Lamm Bergstrom E ^b   Glaves, P ^a   Musgrove, H ^a   Prior, H ^a   Braddock, M ^a   Huby, R ^a   Curwen, J O ^a   Duffy, P ^a   Harmer, Alexander R ^a  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

BP; drug induced; endothelial function; fostamatinib; R406; TK; VEGF

Indexed keywords

FOSTAMATINIB; NITRIC OXIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; OXAZINE DERIVATIVE; PYRIDINE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR FUNCTION; CONSCIOUSNESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; EX VIVO STUDY; FEMORAL ARTERY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; IN VITRO STUDY; ISOLATED HEART; LUNG PARENCHYMA; MALE; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; TELEMETRY; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD PRESSURE; CELL CULTURE; DRUG EFFECTS; INSECT; MOLECULAR GENETICS; MOUSE; NUDE MOUSE; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; SPRAGUE DAWLEY RAT; WISTAR RAT;

ANIMALS; BLOOD PRESSURE; CELLS, CULTURED; HUMANS; INSECTS; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NITRIC OXIDE; ORGAN CULTURE TECHNIQUES; OXAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898640505     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12559     Document Type: Article

References (52)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013) the Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. British Journal of Pharmacology 170: 1676-1705.
2. Al-Zobaidy MJ, Craig J, Brown K, Pettifor G, Martin W, (2011). Stimulus-specific blockade of nitric oxide-mediated dilatation by asymmetric dimethylarginine (ADMA) and monomethylarginine (L-NMMA) in rat aorta and carotid artery. Eur J Pharmacol 673: 78-84.
3. Belcik JT, Qi Y, Kaufmann BA, Xie A, Bullens S, Morgan TK, et al. (2012). Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer. J Am Coll Cardiol 60: 618-625.
4. Bhargava P, (2009). VEGF kinase inhibitors: how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 297: R1-R5.
5. Blasi E, Heyen J, Patyna S, Hemkens M, Ramirez D, John-Baptiste A, et al. (2012). Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function. Cardiovasc Ther 30: 287-294.
6. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, et al. (2006). R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 319: 998-1008.
7. Brave SR, Odedra R, James NH, Smith NR, Marshall GB, Acheson KL, et al. (2011). Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. Int J Oncol 39: 271-278.
8. Chen HX, Cleck JN, (2009). Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6: 465-477.
9. Curwen JO, Musgrove HL, Kendrew J, Richmond GH, Ogilvie DJ, Wedge SR, (2008). Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clin Cancer Res 14: 3124-3131.
10. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. (2011). Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29: 1046-1051.
11. Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, et al. (2012). Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther 92: 503-510.
12. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM, (2009). Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54: 652-658.
13. Franklin PH, Banfor PN, Tapang P, Segreti JA, Widomski DL, Larson KJ, et al. (2009). Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition. J Pharmacol Exp Ther 329: 928-937.
14. Furchgott RF, Zawadzki JV, (1980) the obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376. (Pubitemid 11169009)
15. Gardiner SM, Compton AM, Kemp PA, Bennett T, (1990). Regional and cardiac haemodynamic effects of NG-nitro-L-arginine methyl ester in conscious, Long Evans rats. Br J Pharmacol 101: 625-631. (Pubitemid 20357186)
16. Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, et al. (2011). An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 63: 337-345.
17. Heath EI, Infante J, Lewis LD, Luu T, Stephenson J, Tan AR, et al. (2013). A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemother Pharmacol 71: 565-573.
18. Hillier C, Berry C, Petrie MC, O'Dwyer PJ, Hamilton C, Brown A, et al. (2001). Effects of urotensin II in human arteries and veins of varying caliber. Circulation 103: 1378-1381. (Pubitemid 32220627)
19. Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, et al. (1997). Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 17: 2793-2800. (Pubitemid 28016023)
20. Joannides R, Bellien J, Thuillez C, (2006). Clinical methods for the evaluation of endothelial function- a focus on resistance arteries. Fundam Clin Pharmacol 20: 311-320.
21. Kamendi HW, Brott DA, Chen Y, Litwin DC, Lengel DJ, Fonck C, et al. (2010). Combining radio telemetry and automated blood sampling: a novel approach for integrative pharmacology and toxicology studies. J Pharmacol Toxicol Methods 62: 30-39.
22. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH, (2010). Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 56: 675-681.
23. Kappers MH, de Beer VJ, Zhou Z, Danser AH, Sleijfer S, Duncker DJ, et al. (2012). Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress. Hypertension 59: 151-157.
24. Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A, (2011). Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 16: 432-444.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
26. Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH, (2012). Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens 31: 444-454.
27. Lazarus A, Keshet E, (2011). Vascular endothelial growth factor and vascular homeostasis. Proc Am Thorac Soc 8: 508-511.
28. Lynch J, Regan C, Beatch G, Gleim G, Morabito C, (2013). Comparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vernakalant and flecainide in human isolated vascular and cardiac tissues. J Cardiovasc Pharmacol 61: 226-232.
29. McInnes IB, Schett G, (2007). Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7: 429-442. (Pubitemid 46834849)
30. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
31. McTigue M, Murray BW, Chen JH, Deng YL, Solowiej J, Kania RS, (2012). Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proc Natl Acad Sci U S A 109: 18281-18289.
32. Mayer EL, Dallabrida SM, Rupnick MA, Redline WM, Hannagan K, Ismail NS, et al. (2011). Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension 58: 85-92.
33. Meredith IT, Currie KE, Anderson TJ, Roddy MA, Ganz P, Creager MA, (1996). Postischemic vasodilation in human forearm is dependent on endothelium-derived nitric oxide. Am J Physiol 270: H1435-H1440.
34. Metz JT, Johnson EF, Soni NB, Merta PJ, Kifle L, Hajduk PJ, (2011). Navigating the kinome. Nat Chem Biol 7: 200-202.
35. Nagasawa T, Hye Khan MA, Imig JD, (2012). Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. Clin Exp Pharmacol Physiol 39: 454-461.
36. O'Leary DS, Dunlap RC, Glover KW, (1994). Role of endothelium-derived relaxing factor in hindlimb reactive and active hyperemia in conscious dogs. Am J Physiol 266: R1213-R1219.
37. Rees DD, Palmer RM, Schulz R, Hodson HF, Moncada S, (1990). Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol 101: 746-752. (Pubitemid 20357206)
38. Riccaboni M, Bianchi I, Petrillo P, (2010). Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today 15: 517-530.
39. Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD, (2010). Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 30: 591-601.
40. Smith NR, James NH, Oakley I, Wainwright A, Copley C, Kendrew J, et al. (2007). Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 6: 2198-2208. (Pubitemid 47294748)
41. Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, et al. (2008). Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 14: 3470-3476.
42. Stucker O, Vicaut E, Villereal MC, Ropars C, Teisseire BP, Duvelleroy MA, (1985). Coronary response to large decreases of hemoglobin-O2 affinity in isolated rat heart. Am J Physiol 249: H1224-H1227. (Pubitemid 16171208)
43. Thanigaimani S, Kichenadasse G, Mangoni AA, (2011) the emerging role of vascular endothelial growth factor (VEGF) in vascular homeostasis: lessons from recent trials with anti-VEGF drugs. Curr Vasc Pharmacol 9: 358-380.
44. Thomas GR, Walder CE, Thiemermann C, Vane JR, (1990). Regional vascular resistance and haemodynamics in the spontaneously hypertensive rat: the effects of bradykinin. J Cardiovasc Pharmacol 15: 211-217. (Pubitemid 20040577)
45. University of Edinburgh, Department of Pharmacology (1970). Pharmacological Experiments on Isolated Preparations. E. and S. Livingstone: Edinburgh.
46. Vallance P, Collier J, Moncada S, (1989). Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2: 997-1000. (Pubitemid 19257913)
47. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, et al. (2006). Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24: 1363-1369. (Pubitemid 46621999)
48. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. (2002). ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645-4655.
49. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB, (2010). An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 363: 1303-1312.
50. Wong BR, Grossbard EB, Payan DG, Masuda ES, (2004). Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13: 743-762. (Pubitemid 39028928)
51. Yamabe H, Okumura K, Ishizaka H, Tsuchiya T, Yasue H, (1992). Role of endothelium-derived nitric oxide in myocardial reactive hyperemia. Am J Physiol 263: H8-14.
52. Yang R, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B, et al. (1996). Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 27: 838-844. (Pubitemid 26000416)